Posted by Michael Wonder on 16 Jun 2021
Emmaus Life Sciences announces submission of marketing authorisation application to Swissmedic; Ideogen to manage early access program
15 June 2021 - Emmaus Life Sciences anounced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus' application for marketing authorisation for Endari in Switzerland.
In November 2020, Swissmedic granted Endari orphan drug status.
